Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bojan Vujkovac

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Molecular Genetics and Metabolism|July 15, 2025
Identification of genetic variants associated with Fabry nephropathy progression using whole-exome sequencingTina Levstek, Bojan Vujkovac, Albina Nowak, et al.
Orphanet Journal of Rare Diseases|February 9, 2022
Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?Derralynn A Hughes, Patrício Aguiar, Olivier Lidove, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 28, 2010
Urinary total globotriaosylceramide and isoforms to identify women with Fabry disease: a diagnostic test studyEduard Paschke, Guenter Fauler, Heimo Winkler, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|June 22, 2005
Epoetin responsiveness in peritoneal dialysis patients: a multi-center Slovenian studyJernej Pajek, Maja Bucar-Pajek, Katarina Grego, et al.
Journal of Medical Genetics|October 23, 2015
Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapyDavid G Warnock, Christie P Thomas, Bojan Vujkovac, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 23, 2009
End-stage renal disease in patients with Fabry disease: natural history data from the Fabry RegistryAlberto Ortiz, Bruno Cianciaruso, Marta Cizmarik, et al.
Molecular Genetics and Metabolism|January 3, 2026
A non-coding signature in SHROOM3 is associated with kidney disease progression in Fabry diseaseTina Levstek, Nika Breznik, Kaja Balant Marin, et al.
Drug Design, Development and Therapy|July 18, 2015
Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry diseaseLubor Goláň, Ozlem Goker-Alpan, Myrl Holida, et al.
Orphanet Journal of Rare Diseases|October 21, 2023
Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label studyAleš Linhart, Gabriela Dostálová, Kathy Nicholls, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 4, 2010
Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry RegistryChristoph Wanner, João P Oliveira, Alberto Ortiz, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Molecular Genetics and Metabolism|July 15, 2025
Identification of genetic variants associated with Fabry nephropathy progression using whole-exome sequencingTina Levstek, Bojan Vujkovac, Albina Nowak, et al.
Orphanet Journal of Rare Diseases|February 9, 2022
Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?Derralynn A Hughes, Patrício Aguiar, Olivier Lidove, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 28, 2010
Urinary total globotriaosylceramide and isoforms to identify women with Fabry disease: a diagnostic test studyEduard Paschke, Guenter Fauler, Heimo Winkler, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|June 22, 2005
Epoetin responsiveness in peritoneal dialysis patients: a multi-center Slovenian studyJernej Pajek, Maja Bucar-Pajek, Katarina Grego, et al.
Journal of Medical Genetics|October 23, 2015
Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapyDavid G Warnock, Christie P Thomas, Bojan Vujkovac, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 23, 2009
End-stage renal disease in patients with Fabry disease: natural history data from the Fabry RegistryAlberto Ortiz, Bruno Cianciaruso, Marta Cizmarik, et al.
Molecular Genetics and Metabolism|January 3, 2026
A non-coding signature in SHROOM3 is associated with kidney disease progression in Fabry diseaseTina Levstek, Nika Breznik, Kaja Balant Marin, et al.
Drug Design, Development and Therapy|July 18, 2015
Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry diseaseLubor Goláň, Ozlem Goker-Alpan, Myrl Holida, et al.
Orphanet Journal of Rare Diseases|October 21, 2023
Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label studyAleš Linhart, Gabriela Dostálová, Kathy Nicholls, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 4, 2010
Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry RegistryChristoph Wanner, João P Oliveira, Alberto Ortiz, et al.
Pageof 4